Biotech Startup Funding Has Also Slowed In 2022
After peaking in 2021, venture funding to biotech startups slowed in 2022, with investment on pace to come in at least a third lower than last year’s levels.
The slowdown comes amid a broader pullback in global venture funding. Across all sectors, investment hit its zenith in November and has been cresting downward since. On the exit front, meanwhile, the pace of venture-backed IPOs has slowed to a crawl.
Biotech funding follows the general pattern. In the U.S., biotech startups have raised a total of $16.5 billion so far this year, or about $3.2 billion on average per month. In all of 2021, however, nearly $47 billion went into the space, an average of nearly $4 billion per month.
Downvoting a post can decrease pending rewards and make it less visible. Common reasons:
Submit